Resources

With last week’s news that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has recommended the approval of degludec, we thought we’d give you an overview of this new drug’s pharmacology, the current approval status, trial results, and some of the cardiovascular safety concerns around degludec….

    First Non-invasive CGMS system Approved in Europe. C8 MediSensors, Inc. has announced it received CE Mark approval for its Optical Glucose Monitor System, allowing the device to be marketed in Europe. See Item #5, First Possible Non-Invasive Continuous Glucose Monitor Approved in Europe, in today’s newsletter. 

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a randomized trial designed to compare two fixed doses of dabigatran, each administered in a blinded manner, with open-label use of warfarin in patients who had atrial fibrillation and were at increased risk for stroke….

For diabetic kidney recipients, early intensive glycemic control might reduce delayed graft function (DGF) but with a higher risk of rejection….

An FDA advisory committee voted 8-4 Thursday, November 8, in favor of approval of a new ultra-long-acting insulin Tresiba and its mixed insulin Ryzodeg for type 1 and type 2 diabetes….

Obese people with diabetes who lost weight didn’t lower their risk of having a heart attack or stroke…. 

C8 MediSensors, Inc. has received Europe’s CE Mark approval for its Optical Non-Invasive CGM System….

Physicians who don’t manage their online presence run the risk of failing to attract new patients…. 

Middle-aged people who walk briskly for as little as 75 minutes per week may live 1.8 years longer, even if they are overweight…. 

According to the CDC, the death rate from diabetes among children and adolescents has fallen by more than 60% since the late 1960s….